Bennett named DrSN publisher
NEW YORK Drug Store News, Pharmacy Practice, PharmacyTech News, Retail Clinician and Specialty Pharmacy magazines, as well as all Drug Store News electronic media products.—Lebhar-Friedman Inc., parent company of The Drug Store News Group, last month named Wayne Bennett publisher of the group, which includes
The move, which became effective just prior to the holidays, acknowledges the considerable contributions Bennett has made to the Drug Store News franchise over a highly successful 15-year career with the company. Bennett, who most recently served as associate publisher of the group and national sales manager prior to that, has played an instrumental role in the overall growth of the enterprise from the single flagship Drug Store News print edition to the group of publications and e-media products that comprise The Drug Store News Group today.
Bennett succeeds John Kenlon, who in 2009 was named VP and group publisher for Lebhar-Friedman’s retail division, which includes The Drug Store News Group as well as Chain Store Age, Retailing Today and Home Channel News, including all print and electronic products.
“Wayne has a genuine passion for retail pharmacy and wants the industry to succeed—not just Drug Store News,” Kenlon said. “For that reason, suppliers and retailers want to work with him; they know he will do everything he can to help improve their businesses.”
Bennett first joined Lebhar-Friedman in October 1995 as area manager for Drug Store News.
Walgreens offering free review sessions to Medicare Part D beneficiaries
DEERFIELD, Ill. Walgreens now is offering free review sessions to Medicare Part D beneficiaries at all of its more than 7,100 pharmacies throughout the country.
Following the open enrollment period for Medicare Part D insurance plans, Walgreens is assisting those beneficiaries who’ve made changes to their prescription drug coverage. Review sessions with Walgreens pharmacists are available daily by appointment through Jan. 31, and are designed to help patients maximize their plan benefits.
Review sessions include:
- A review of beneficiary’s current medications, tiers within their selected plan, co-pays and cost-savings opportunities
- Discussion of available health and wellness services including pneumonia and shingles vaccinations and 90-day prescription benefits
- Checks for potential drug interactions
Watson files FDA application for generic LoSeasonique
MORRISTOWN, N.J. Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new drug application to the Food and Drug Administration for an oral contraceptive.
Watson is seeking approval to market its levonorgestrel and ethinyl estradiol (0.10-mg/0.02-mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, a subsidiary of Teva. Watson’s levonorgestrel and ethinyl estradiol product is a generic version of Teva’s LoSeasonique, which is indicated for the prevention of pregnancy.
On Nov. 23, 2009, pursuant to the Hatch-Waxman Act, Watson notified Duramed that its ANDA requesting approval from the FDA for a generic version of LoSeasonique contained a paragraph IV certification asserting that the LoSeasonique patent is invalid, unenforceable and/or not infringed. Teva Women’s Health filed suit against Watson on Jan. 6, 2010 in the U.S. District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 7,615,545. Based on available information, Watson believes it may be entitled to 180 days of generic market exclusivity or shared exclusivity should its product receive approval.